ADO
data caveat$36M3mo
Anteotech
Biotechnology · Diagnostics
Chemical and materials technology company commercialising AnteoBind (diagnostics surface chemistry) and advanced silicon anode battery materials.
Data HealthFiling4C overdue · Dec 202580d
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$1.4M
Dec 2025 4C
Runway
3moCRITICAL
Based on Dec 2025 4C
Market Cap
$36M
Burn Rate
$1.3M/qtr
Dec 2025 4C
Shares Outstanding
3.0B
Pipeline Assets
3
Latest Insight(1)
1 Mar 2026Half YearHalf Year Results and Operational Update Presentation
Cash$1.6M·
3M Price
ADO.ASX$0.012-42.9% 3M
Low $0.010High $0.021
Pipeline Assets (3)
Ultranode 70Silicon anode battery materials
PreclinicalAnteo XSilicon anode crosslinker additive
PreclinicalAnteoBindDiagnostics conjugation platform
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Catalysts (2)
Wyon AG commercial cell evaluation results (Ultranode 70)
UpcomingExpectedarrow_upwardHigh30 Apr 2026
Battery pipeline lead conversion to JDAs/sales
UpcomingSpeculativearrow_upwardHigh30 June 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| Wyon AG commercial cell evaluation results (Ultranode 70) | data readout | Expected | arrow_upwardHigh | 30 Apr 2026 |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.